Phase 2/3 update: Retatrutide reduced liver fat 86%, dropped systolic BP up to 14 mmHg, lowered triglycerides ~35–40%, and reduced A1c up to 2.0%.
Retatrutide · Secondary Endpoints · Updated May 2026
Retatrutide beyond weight loss — what the secondary endpoints show.
The 28.7% weight number is the headline. The cardiometabolic, hepatic, glycemic, cognitive, and addiction-related signals coming out of the Phase 2 and Phase 3 program may matter as much — and in some patient profiles, more.
By Joshua Hare, DO · Limitless Performance Medicine
The frame
Most coverage stops at the weight number. The full picture is bigger.
It is reasonable that the headlines led with weight loss. A 28.7% Phase 3 weight-loss figure is the largest ever reported in obesity pharmacology. But the same Phase 2 and Phase 3 program is producing data on liver, blood pressure, lipids, glucose, and emerging signals on cognition and substance-use cravings that are worth reading on their own merits.
For patients with metabolic disease, the secondary endpoints are not actually secondary. A patient with MASH, prediabetes, hypertension, and dyslipidemia who happens to also have obesity may benefit more from the cardiometabolic and hepatic effects than from the weight loss specifically. That patient — common in any U.S. internal medicine practice — is closer to the modal candidate than the patient seeking 30 lb of cosmetic weight reduction.
This article catalogs what the Phase 2 and Phase 3 program has shown beyond the weight number. Where evidence is robust, I will say so. Where it is preclinical or extrapolated from class data, I will say that too.
86%
Liver fat reduction
12 mg dose, 48 weeks, Phase 2a (Nature Medicine 2024). 93% reached normal liver fat.
−14 mmHg
Systolic BP drop
At highest dose, Phase 2/3 data. Comparable to a high-quality antihypertensive.
−2.0%
A1c reduction
TRANSCEND-T2D-1 (March 2026). The largest A1c effect in any incretin trial to date.
"Reading the Phase 2/3 retatrutide data narrowly as a weight-loss drug is like reading a Tesla spec sheet only for the 0–60. The other systems engaged are the more interesting clinical story."
Evidence: Phase 2a published · Phase 3 reading out 2026
Endpoint 01 — Hepatic
Liver fat reduction: the strongest signal outside of weight.
The 2024 Phase 2a trial published in Nature Medicine evaluated retatrutide specifically in adults with metabolic dysfunction-associated steatotic liver disease (MASLD). The results were remarkable enough that they reframed the drug's clinical positioning.
86% relative reduction in liver fat content (MRI-PDFF) at 48 weeks on the 12 mg dose, vs. 0% on placebo.
93% of participants on the 12 mg dose achieved normal liver fat (< 5%) — meaning their MRI-measured hepatic steatosis effectively resolved.
89% achieved normal liver fat on the 8 mg dose. Even the lower doses produced clinically meaningful effects.
The 81.7% reduction at 8 mg outperformed published Phase 3 results from any other GLP-1 or GLP-1/GIP agent in this indication.
The TRIUMPH program includes a dedicated MASH trial (TRIUMPH-3 area, ClinicalTrials.gov NCT06859268) reading out in 2026 that uses biopsy endpoints — resolution of steatohepatitis and improvement in fibrosis without worsening of either. The MRI data has already shifted the lipid/inflammatory milieu of the liver. The biopsy data will determine whether structural reversal follows.
"If the Phase 3 MASH biopsy data confirms what the Phase 2 imaging predicts, retatrutide may emerge as the most effective MASLD/MASH therapy ever made — full stop, not in the 'for an obesity drug' category."
Why glucagon matters here: The glucagon receptor activation that distinguishes retatrutide from tirzepatide drives hepatic lipolysis directly. Glucagon mobilizes stored fat from the liver. This is the mechanistic reason a triple agonist outperforms a dual agonist on liver outcomes — the biology favors the molecule.
Evidence: Phase 2/3 published
Endpoint 02 — Cardiometabolic
Blood pressure, lipids, and inflammation — the cardiovascular package.
Beyond weight, the Phase 2 and Phase 3 retatrutide program reported clinically meaningful effects on virtually every measured cardiometabolic parameter. The magnitude is comparable to dedicated single-purpose drugs:
Marker
Effect on retatrutide
Clinical context
Systolic blood pressure
Up to −14.0 mmHg
Comparable to a thiazide or ACE inhibitor
Total cholesterol
~ −15 to −18%
Approaching low-dose statin territory
LDL cholesterol
~ −12 to −22%
Meaningful for cardiovascular risk reduction
Triglycerides
~ −35 to −40%
Larger reduction than fibrates produce in many patients
Non-HDL cholesterol
Significant reduction
Better risk marker than LDL alone
hs-CRP
Significant reduction
Reflects systemic inflammation; tracks with cardiovascular risk
Waist circumference
Substantial reduction
Visceral fat marker; correlates with metabolic disease
The cardiovascular outcomes trial (CVOT) within the TRIUMPH program is the readout that will turn surrogate markers into hard endpoints — fewer heart attacks, fewer strokes, fewer cardiovascular deaths. That trial has not yet read out. Until it does, retatrutide cannot make the cardiovascular mortality claim that semaglutide can after SELECT.
What we can say honestly: the surrogate-marker package retatrutide produces is the most metabolically active profile of any obesity drug to date. Whether that translates 1:1 into mortality benefit is the empirical question CVOT will answer.
Evidence: Phase 3 (TRANSCEND-T2D-1, March 2026)
Endpoint 03 — Glycemic
A1c and type 2 diabetes — the largest reduction in incretin history.
In March 2026, Eli Lilly announced topline results from TRANSCEND-T2D-1, the first Phase 3 readout for retatrutide in type 2 diabetes. The headline:
Up to 2.0% A1c reduction on retatrutide. For context, semaglutide produces ~1.5% A1c reduction in similar trials; tirzepatide ~2.1%. Retatrutide is in the top tier of glycemic effect.
Retatrutide met the primary endpoint and all key secondary endpoints in the trial.
Patients also saw substantial weight reduction in the same population — diabetes patients typically lose less weight on these drugs than patients without diabetes, but retatrutide narrowed the gap.
For a patient with type 2 diabetes that has not responded adequately to metformin alone, retatrutide may offer a dual benefit profile that is hard to match with any single existing agent: comparable glycemic efficacy to tirzepatide plus the body-composition and cardiometabolic profile of the triple agonist. That is a powerful combination.
The full TRANSCEND program (T2D trials 1–6) is reading out through 2026. Retatrutide will likely be the rare drug that submits NDAs simultaneously for obesity and type 2 diabetes — accelerating the pace at which it reaches the patient populations that need it most.
Evidence: Preclinical · class-level extrapolation
Endpoint 04 — Cognitive
Cognitive and neuroinflammatory effects — preclinical, but suggestive.
Direct human cognitive trial data on retatrutide does not yet exist. There are no registered clinical trials specifically evaluating retatrutide for cognitive endpoints, dementia, or neurodegenerative disease as of May 2026. That is the honest framing.
What the literature does show is increasingly persuasive class-level and preclinical data that GLP-1 receptor agonists, dual agonists, and triple agonists may be cognitively meaningful drugs:
A January 2026 preclinical study (rat model) showed that retatrutide preserved spatial learning and short-term memory in diabetic animals, with reduced TNF-α and attenuated neuroinflammation.
Preclinical work on dual and triple incretin agonists has demonstrated reductions in amyloid-β and tau pathology in Alzheimer's models, reduced neuroinflammation, and promotion of neurogenesis and synaptic plasticity.
Triple and dual agonists appear to produce stronger neuroprotective effects than single GLP-1 agonists in head-to-head preclinical comparisons.
Multi-incretin agonists cross the blood-brain barrier and engage central receptors — the mechanism is plausible.
For human data, the closest analogues come from the broader GLP-1 class. Liraglutide showed signals in mild-to-moderate Alzheimer's disease in a Phase 2b trial published in Nature Medicine (2025). Semaglutide and Alzheimer's trials are ongoing.
"I do not promise patients cognitive benefit from retatrutide because there is no human trial that earns the promise yet. I do tell them the mechanism is plausible, the preclinical signal is real, and we'll know more in 2027–2028 as Phase 3 readouts mature."
If the cognitive signal holds up in dedicated human trials, retatrutide would represent an entirely new category of therapy — a drug that simultaneously addresses metabolic disease (a major risk factor for dementia) and may directly modulate neurodegeneration. That is speculative today. It is also one of the most interesting open clinical questions in the GLP-1 class.
Evidence: Emerging human data (class-level) · retatrutide-specific data pending
Endpoint 05 — Addiction & substance-use cravings
Alcohol, nicotine, opioids — the reward-pathway story.
One of the most clinically interesting class-level findings of the GLP-1 era is that these drugs appear to reduce cravings for alcohol, nicotine, and other substances of abuse. The mechanism is reasonably well-understood: GLP-1 receptors are expressed in the mesolimbic reward circuitry (ventral tegmental area, nucleus accumbens), and agonism dampens the dopaminergic response to substance-related cues.
What the human data actually shows:
Semaglutide in alcohol use disorder (JAMA Psychiatry, 2025). A randomized clinical trial of low-dose once-weekly semaglutide produced significant reductions in alcohol craving and reductions in some weekly consumption measures over a 9-week treatment period. The trial was a proof-of-concept; larger Phase 3 trials are in progress.
Tirzepatide AUD trial. A registered clinical trial (NCT06994338) is currently evaluating tirzepatide in alcohol use disorder. The dual-agonist may produce stronger effects than semaglutide alone.
Observational data on nicotine, opioids, and other substances. Real-world data from electronic health records and large databases consistently shows that patients on GLP-1 therapy for diabetes or obesity have lower rates of substance use, smoking initiation, and opioid prescription refill behavior.
Retatrutide-specific addiction trials. None registered as of May 2026. The triple-agonist mechanism (which adds glucagon receptor agonism) may amplify the reward-pathway effect, but this is mechanistic speculation, not empirical observation.
Where this matters clinically: a patient with co-occurring obesity, type 2 diabetes, MASLD, hypertension, and an alcohol problem is not a rare patient in any U.S. clinical practice. They are common. A drug that addresses multiple components of that picture simultaneously — even if the addiction effect is modest individually — has integrated value that exceeds any single intervention.
"Patients on tirzepatide and semaglutide tell me, unprompted, that they are drinking less. Sometimes a lot less. The clinical signal is consistent enough that I now ask about it as a screening question — and the data continues to catch up to what patients have been describing for two years."
Clinical implications
What this changes about how we think about retatrutide.
It is not a weight-loss drug. It is a metabolic-disease drug whose most prominent effect is weight loss. The framing matters because the patient populations who benefit most are not always the ones seeking the highest scale loss.
For MASLD/MASH patients, retatrutide may emerge as the most effective therapy ever made for the condition, full stop. The 86% liver fat reduction is the kind of effect size that reframes a disease.
For metabolic-syndrome patients, the BP/lipid/A1c/inflammation package is comparable to what would otherwise require three to four separate medications. Polypharmacy reduction is itself a clinical good.
For patients with co-occurring substance-use issues, the GLP-1 class is showing real signal. Retatrutide-specific trials are not registered, but the mechanism extrapolates. We discuss this honestly with patients.
For dementia risk, the data is preclinical and class-level. We do not promise it. We do say the mechanism is plausible and the broader literature is becoming hard to ignore.
For prescribing decisions today (May 2026), retatrutide is not available — it is investigational. Patients with the picture described above are running on tirzepatide or semaglutide with the strongest available adjunct architecture, with the plan to evaluate retatrutide when it launches.
Frequently asked
Beyond weight loss, asked and answered.
If retatrutide is so good for liver, can I get it for MASH today?
No. Retatrutide is investigational. It is not FDA-approved for MASH, MASLD, or any other indication. Patients with MASH today have semaglutide (some evidence), tirzepatide (some evidence), and resmetirom (FDA-approved for MASH specifically, March 2024) as approved options. We can discuss which fits your picture during consultation.
Will retatrutide replace statins or BP medications?
For some patients, possibly. The lipid and BP effects are large enough that some patients on retatrutide may be able to discontinue or reduce a statin or antihypertensive. That deprescribing decision requires careful monitoring and should not be made unilaterally. We design taper plans with the patient's full medication list in view.
Should patients with prediabetes wait for retatrutide?
No. Tirzepatide is currently the most effective approved option for prediabetes-to-T2D conversion prevention, with very strong glycemic data. Starting now and evaluating retatrutide at launch is the conservative recommendation.
What about retatrutide for Alzheimer's prevention?
There is no human trial supporting that use today. The preclinical signal is interesting and the mechanism is plausible — but plausibility does not equal evidence in clinical decisions. We do not prescribe based on speculative cognitive endpoints.
Will the addiction effect work for me?
Class-level data suggests it might. We do not promise it, and we do not prescribe a GLP-1 specifically for substance use disorder outside of a clinical trial. We do tell patients that many of them experience reduced cravings as a side benefit, and we screen for it during follow-up.
Where do I read the Phase 3 weight-loss data?
Our Retatrutide 2026 article covers the TRIUMPH-4 readout (28.7% weight loss) in detail, plus mechanism and FDA timeline.
Editorial note. This article summarizes published Phase 2 and Phase 3 data and emerging preclinical literature on retatrutide as of May 2026. Retatrutide is an investigational drug and is not FDA-approved for any indication. Effect sizes reported are mean values from published trials; individual response varies. The cognitive and addiction-related literature cited is largely preclinical or class-level (semaglutide, liraglutide, tirzepatide); retatrutide-specific human trials in those indications are not yet registered. Nothing here is a prescription. Decisions about pharmacologic therapy require physician evaluation, lab work, and ongoing monitoring.
The full picture is the real story.
Limitless designs comprehensive metabolic protocols anchored to your labs and your goals — not just to a single endpoint. When retatrutide reaches the market, it joins our formulary. Until then, we use what's available — well.